重型再生障碍性贫血免疫抑制治疗后克隆演化及髓系肿瘤的预测因素
该研究评估了1989-2020年接受免疫抑制治疗的重型再生障碍性贫血患者克隆演化的预测因素、遗传特征及长期结局。663例患者中95例发生克隆演化,治疗前年龄>48岁和中性粒细胞绝对计数>0.87×10^9/L是高危演化的强预测因素。高危克隆演化患者5年总生存率为37%,低危为94%,高危患者接受造血干细胞移植可改善总生存。
要点
- 治疗前年龄>48岁和ANC>0.87×10^9/L是高危克隆演化的强预测因素。
- 高危克隆演化患者5年OS为37%,低危患者为94%。
- 高危患者接受HSCT可改善OS,艾曲泊帕未增加高危演化。
核心结论
- 治疗前年龄>48岁和ANC>0.87×10^9/L是高危克隆演化的强预测因素。
- 高危克隆演化患者5年OS为37%,低危患者为94%,高危患者接受HSCT可改善OS。
- 艾曲泊帕未增加高危克隆演化。
- 免疫抑制治疗后6个月检测到RUNX1、剪接因子和ASXL1体细胞突变可预测高危克隆演化。
研究设计与样本
- 研究纳入1989-2020年接受免疫抑制治疗的重型再生障碍性贫血患者,共663例。
- 克隆演化分为高危(符合WHO标准的明显髓系肿瘤或孤立7号染色体异常/复杂核型不伴发育异常或明显髓系肿瘤)和低危(非7号或非复杂染色体异常不伴形态学发育异常或髓系肿瘤证据)。
- 采用Fine-Gray竞争风险回归模型进行单因素和多因素分析确定预测因素。
- 在演化患者和407例免疫抑制治疗后6个月的患者中评估髓系肿瘤基因的体细胞突变。
主要发现
- 663例重型再生障碍性贫血患者中95例发生克隆演化。
- 治疗前年龄>48岁和ANC>0.87×10^9/L是高危演化的强预测因素。
- 高危克隆演化患者5年OS为37%,低危患者为94%。
- 高危患者接受HSCT可改善OS。
- 艾曲泊帕未增加高危演化。
关键数值与推荐
- 高危克隆演化定义:符合WHO标准的明显髓系肿瘤(发育异常、MPN或急性白血病)或孤立7号染色体异常/复杂核型不伴发育异常或明显髓系肿瘤。
- 低危克隆演化定义:非7号或非复杂染色体异常不伴形态学发育异常或髓系肿瘤证据。
- 高危演化强预测因素:治疗前年龄>48岁和ANC>0.87×10^9/L。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Predictors, genetic characteristics, and long-term outcomes of patients with SAA who clonally evolved after immunosuppressive therapy (IST) were assessed. SAA patients were treated with IST from 1989-2020. Clonal evolution was categorized as "high-risk" (overt myeloid neoplasm [meeting WHO criteria for dysplasia, MPN or acute leukemia] or isolated chromosome-7 abnormality/complex karyotype without dysplasia or overt myeloid neoplasia) or "low-risk" (non-7 or non-complex chromosome abnormalities without morphological evidence of dysplasia or myeloid neoplasia). Univariate and multivariate analysis using Fine-Gray competing risk regression model determined predictors. Long-term outcomes included relapse, overall survival (OS) and hematopoietic stem cell transplant (HSCT). Somatic mutations in myeloid cancer genes were assessed in evolvers and in 407 patients 6 months after IST. Of 663 SAA patients, 95 developed clonal evolution. Pre-treatment age >48 years and ANC > 0.87 × 109/L were strong predictors of high-risk evolution. OS was 37% in high-risk clonal evolution by 5 years compared to 94% in low-risk. High-risk patients who underwent HSCT had improved OS. Eltrombopag did not increase high-risk evolution. Splicing factors and RUNX1 somatic variants were detected exclusively at high-risk evolution; DNMT3A, BCOR/L1 and ASXL1 were present in both. RUNX1, splicing factors and ASXL1 somatic mutations detected at 6 months after IST predicted high-risk evolution.
引用
- Groarke EM, Patel BA, Shalhoub R, et al. Predictors of clonal evolution and myeloid neoplasia following immunosuppressive therapy in severe aplastic anemia. Leukemia. 2022. PMID: 35896822. doi:10.1038/s41375-022-01636-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。